Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study.
Pediatr Blood Cancer
; 65(12): e27381, 2018 12.
Article
en En
| MEDLINE
| ID: mdl-30230231
ABSTRACT
Little is known about the challenging treatment of pediatric patients with hemophilia B and inhibitors due to disease rarity. We describe three patients diagnosed in childhood and followed up to 9 years. All three had allergic reactions to Factor IX, but two were later safely treated for bleeding episodes with activated prothrombin complex concentrates (APCC = FEIBA). The third was given only recombinant activated Factor VIIa. Based on ex vivo thrombin generation analysis, a new alternative treatment of combined bypassing agents was administered for bleeding episodes and several minor surgical procedures with no treatment-associated adverse events or thrombosis.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Factores de Coagulación Sanguínea
/
Trombina
/
Factor VIIa
/
Hemofilia B
Límite:
Adolescent
/
Child, preschool
/
Humans
/
Male
Idioma:
En
Revista:
Pediatr Blood Cancer
Asunto de la revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Año:
2018
Tipo del documento:
Article
País de afiliación:
Israel